相似文献
1
Retention of atherogenic lipoproteins in atherogenesis.
Cell Mol Life Sci. 2004 Jan;61(1):4-9. doi: 10.1007/s00018-003-3262-x.
2
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.
Nature. 2002 Jun 13;417(6890):750-4. doi: 10.1038/nature00804.
3
Role of extracellular retention of low density lipoproteins in atherosclerosis.
Curr Opin Lipidol. 2000 Oct;11(5):451-6. doi: 10.1097/00041433-200010000-00002.
4
Nonoxidative modifications of lipoproteins in atherogenesis.
Annu Rev Nutr. 1999;19:123-39. doi: 10.1146/annurev.nutr.19.1.123.
5
The response-to-retention hypothesis of atherogenesis reinforced.
Curr Opin Lipidol. 1998 Oct;9(5):471-4. doi: 10.1097/00041433-199810000-00012.
6
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
J Intern Med. 2005 Nov;258(5):395-410. doi: 10.1111/j.1365-2796.2005.01556.x.
7
Mechanism of lipoprotein retention by the extracellular matrix.
Curr Opin Lipidol. 2004 Oct;15(5):505-14. doi: 10.1097/00041433-200410000-00003.
8
The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans.
J Biol Chem. 1998 Dec 25;273(52):35355-61. doi: 10.1074/jbc.273.52.35355.
9
Apolipoproteins, the lipid hypothesis and ischaemic heart disease.
Przegl Lek. 1985;42(8):602-6.
10
Lipoproteins, apolipoproteins and coronary artery disease.
Ric Clin Lab. 1982 Jan-Mar;12(1):101-6. doi: 10.1007/BF02909314.
引用本文的文献
1
Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis.
Int J Biol Sci. 2023 Aug 21;19(14):4493-4510. doi: 10.7150/ijbs.86475. eCollection 2023.
2
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
Front Endocrinol (Lausanne). 2020 Jul 28;11:474. doi: 10.3389/fendo.2020.00474. eCollection 2020.
3
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Curr Atheroscler Rep. 2019 May 20;21(8):27. doi: 10.1007/s11883-019-0791-9.
4
Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
Curr Atheroscler Rep. 2016 Oct;18(10):59. doi: 10.1007/s11883-016-0614-1.
5
Implication of vitamin A deficiency on vascular injury related to inflammation and oxidative stress. Effects on the ultrastructure of rat aorta.
Eur J Nutr. 2012 Feb;51(1):97-106. doi: 10.1007/s00394-011-0198-z. Epub 2011 Apr 22.
6
Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression.
Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1723-30. doi: 10.1161/ATVBAHA.108.173344. Epub 2008 Jul 31.
本文引用的文献
1
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee.
Circulation. 2008 Jan 15;117(2):296-329. doi: 10.1161/CIRCULATIONAHA.107.188209. Epub 2007 Dec 10.
2
Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Ann N Y Acad Sci. 2007 Sep;1110:315-8. doi: 10.1196/annals.1423.033.
3
Invasive treatment performed for acute myocardial infarction in a patient with immune thrombocytopenic purpura.
Int J Cardiol. 2008 Jul 21;127(3):e183-5. doi: 10.1016/j.ijcard.2007.05.075. Epub 2007 Jul 31.
4
5
Coronary revascularization in a patient with immune thrombocytopenic purpura.
J Chin Med Assoc. 2006 Sep;69(9):436-8. doi: 10.1016/S1726-4901(09)70287-4.
6
Primary percutaneous coronary intervention for acute myocardial infarction with idiopathic thrombocytopenic purpura: a case report.
J Korean Med Sci. 2006 Apr;21(2):355-7. doi: 10.3346/jkms.2006.21.2.355.
7
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
JAMA. 2006 Apr 5;295(13):1519-30. doi: 10.1001/jama.295.13.joc60038. Epub 2006 Mar 14.
8
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
N Engl J Med. 2006 Apr 6;354(14):1464-76. doi: 10.1056/NEJMoa055443. Epub 2006 Mar 14.
9
Myocardial infarction associated with intravenous immune globulin.
Ann Pharmacother. 2005 Dec;39(12):2114-8. doi: 10.1345/aph.1G104. Epub 2005 Nov 15.
10
[Percutaneous transluminal coronary angioplasty in a patient with idiopathic thrombocytopenic purpura].
Arq Bras Cardiol. 2005 Apr;84(4):337-9. doi: 10.1590/s0066-782x2005000400012. Epub 2005 May 2.
Zotero 插件